Capital increase of 31,250 shares in Orphazyme A/S as a result of vesting and exercise of Matching Shares
Company Registration No. 32266355
Copenhagen, Denmark, July 31, 2020 – Orphazyme A/S (ORPHA.CO), a late-stage biopharmaceutical company harnessing the amplification of the Heat-Shock Protein in order to develop and commercialize novel therapeutics for the treatment of neurodegenerative orphan diseases, today announces that a share capital increase has been registered with the Danish Business Authority as a result of the vesting and exercise of Matching Shares. A total of 31,250 shares of nominally DKK 1 each have been issued by the Company at a subscription price per Matching Share of DKK 1.
Reference is made to company announcement no. 43/2020 of July 29, 2020.
Following the share capital increase, the total nominal share capital will be DKK 27,079,630, divided into 27,079,630 shares each with a nominal value of DKK 1. Each share carries one vote at Orphazyme's general meetings and accordingly the total number of voting rights of the company are 27,079,630. Updated Articles of Association can be found at www.orphazyme.com.
For additional information, please contact
Anders Vadsholt, CFO +45 28 98 90 55
About Orphazyme A/S
Orphazyme is a biopharmaceutical company pioneering the Heat-Shock Protein response for the treatment of neurodegenerative orphan diseases. The company is focused on developing therapies for diseases caused by protein misfolding, protein aggregation, and lysosomal dysfunction. Arimoclomol, the company’s lead candidate, is in clinical development for four orphan diseases: Niemann-Pick disease Type C (NPC), Gaucher Disease, sporadic Inclusion Body Myositis (sIBM), and Amyotrophic Lateral Sclerosis (ALS). The Denmark-based company is listed on Nasdaq Copenhagen (ORPHA.CO). For more information, please visit www.orphazyme.com.
This company announcement may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this company announcement about future events, including the clinical development and potential benefits of arimoclomol for Gaucher disease, NPC, sIBM and ALS, are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could”, and other words and terms of similar meaning or the negative thereof . Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results, performance, or achievements to be materially different from the expected results, performance, or achievements expressed or implied by such forward-looking statements. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.
- 44-2020 Capital increase of 31,250 shares in Orphazyme AS as a result of vesting and exercise of Matching Shares
Upcoming Life Sciences Events
- August 2020
- ChinaBio® Partnering Forum 2020 Digital
- Biotechgate Digital Partnering Event
- September 2020
- Basel: Pharma-Biotech Product & Company Valuation
Latest company news
There are currently no news available for this portal